ROCKVILLE, Md. – NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for a pilot study evaluating the company’s lead drug candidate, NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), in progressive...
research News
COLUMBUS, Ohio — Neucore Bio, an early-stage biotechnology company advancing the therapeutic potential of non-viral, engineered exosomes, today announced the receipt of a $350,000 STTR Phase I grant from the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH) to evaluate the Company’s targeted...
MELBOURNE, Australia — Neuren Pharmaceuticals Limited today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across multiple efficacy measures. Improvements were consistently seen across many of the core PMS characteristics....
Utrecht, Netherlands and Vienna, Austria – Neuroblastoma mainly affects toddlers and young children – in the EU region there are 1500 new cases per year. Neuroblastoma is a malignant tumor of the peripheral nervous system and around 50% of patients are high-risk cases. Recurrences occur frequently, and conventional therapies are...
SAN DIEGO, Calif. — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal hyperplasia (CAH) and acknowledges the frustrations and challenges experienced by the community in managing the condition. “We...
Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical Outcomes Findings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual Meeting SAN DIEGO, Calif. — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented today a systematic literature review illustrating the...
NEW YORK – Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced results of a well-controlled non-human primate study, which demonstrate that route of adeno-associated virus (AAV) administration plays a critical role in optimizing gene therapy delivery to key...
Indianapolis, Ind. – Alois Alzheimer recognized more than a century ago the role of neuroinflammation in the development of the disease that would bear his name. “If you actually go back to his original drawings, he was drawing the cells, which today we know are microglia,” immune cells of the...
WUHAN, China and SAN DIEGO, Calif. — Neurophth Therapeutics, Inc. announced today that the last patient has been enrolled in Phase I/II clinical trial of Opvika® (Esonadogene Imvoparvovec) for the treatment of Leber hereditary optic neuropathy caused by ND4 mutation (ND4-LHON). Neurophth is conducting a Phase I/II, single-arm, multi-center study aimed...
Jerusalem, Israel – In a compelling Genomic Press Interview published in Brain Medicine on September 25, 2024, Professor Hermona Soreq of the Hebrew University of Jerusalem in Israel unveils the profound implications of her groundbreaking research on the cholinergic system and small RNA regulators in brain-body communication. Prof. Soreq, holder...